? PROTEOMICS SHARED RESOURCE (PSR) The PSR provides expertise and access to state-of-the-art instrumentation for proteomics experiments. The PSR is embedded within the OSU Campus Chemical Instrument Center, offering competitive pricing and exceptional service by leveraging generous support from the Office of Research and Colleges, and grants from the NIH. During the last review, the PSR was rated Outstanding as part of the Analytics Shared Resource Group, with three addressable comments to reduce turn-around time, a perceived drop in percent users actually due to an increase of non-cancer users as an OSU facility, and perceived duplicative services. Major services include: 1) consultation for sample preparation, MS experiment design, data analysis, and timelines; 2) protein identification using state-of-the-art MS on a variety of sample matrices; 3) in depth protein characterization including, but not limited to, post-translational modifications, protein variant/mutations, protein truncation sites detection, alternate splice form detection, de novo protein sequencing, protein cross-linking, and protein-protein interactions; 4) protein quantification using label-free (spectral counts and/or relative intensity) or stable isotope label techniques (SILAC or ITRAQ/TMT), quantitative MALDI tissue imaging, and targeted mass spectrometry; and 5) data analysis provided with the BISR using commercial and in-house developed software platforms. Major equipment has been enhanced in the past 5 years through three NIH S10 grants and a funded P41 Resource Center for methods development.
PSR Specific Aims are to: 1) provide advanced mass spectrometry-based proteomics services; 2) provide innovative proteomic data analytics and bioinformatics platforms to facilitate user interpretation; and, 3) provide consultation on experimental design and training on self-operated MS instruments. Over the current funding cycle, the PSR provided key services in support of 44 publications (5 > 10 impact factor), 380 users, and 8 NCI grants, including 1 K22, 1 P01, 4 R01s, 1 R33 and 1 U01. The PSR is critical to the OSUCCC research priorities of immuno-oncology, translational genomics, cancer engineering and cancer prevention and survivorship. Advanced analytical platforms allow researchers to discover novel differentially expressed proteins in serum, urine, BAL fluid, saliva, frozen tissues, formalin fixed tissues, cell culture media, and cell lysates. Given the robust OSUCCC recruitment, demand for services and new technologies will increase. The GSR will expand its staff, instrumentation and services before capacity is reached. To address this, planned new services are being implemented or expanded (informatics services with BISR, capillary electrophoresis and ion mobility methods, tissue imaging, and structural biology using native MS, as developed by a P41 Resource grant). Over the next funding period, the PSR will be a member of the Immune Monitoring and Discovery Platform. The annual budget of the PSR is $1,993,101, yet the CCSG request is $158,381. Thus, the PSR leverages extensive institutional support and seeks only 7.9% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090017
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Wang, Jin-Ting; Xie, Wen-Quan; Liu, Fa-Quan et al. (2018) NADH protect against radiation enteritis by enhancing autophagy and inhibiting inflammation through PI3K/AKT pathway. Am J Transl Res 10:1713-1721
Karpurapu, Manjula; Lee, Yong Gyu; Qian, Ziqing et al. (2018) Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis. Oncotarget 9:10606-10620
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Tasselli, Giorgia; Filippucci, Sara; Borsella, Elisabetta et al. (2018) Yeast lipids from cardoon stalks, stranded driftwood and olive tree pruning residues as possible extra sources of oils for producing biofuels and biochemicals. Biotechnol Biofuels 11:147
Moliva, J I; Hossfeld, A P; Canan, C H et al. (2018) Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner. Mucosal Immunol 11:968-978
Suarez-Kelly, Lorena P; Akagi, Keiko; Reeser, Julie W et al. (2018) Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. Cold Spring Harb Mol Case Stud 4:
Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna et al. (2018) MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget 9:19961-19979
McRee, Annie-Laurie; Shoben, Abigail; Bauermeister, Jose A et al. (2018) Outsmart HPV: Acceptability and short-term effects of a web-based HPV vaccination intervention for young adult gay and bisexual men. Vaccine 36:8158-8164

Showing the most recent 10 out of 2602 publications